ArticleGenetic epidemiology2021
A novel transcriptional risk score for risk prediction of complex human diseases.
Article in Genetic epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Single-cell transcriptomics provides insights into the stress-immune interplay and informs disease risk.Cell genomics · 2026Article
- Article
- A review of methods and software for polygenic risk score analysis.PeerJ. Computer science · 2025Article
- The impact of Bayesian optimization on feature selection.Scientific reports · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Recently polygenetic risk score (PRS) has been successfully used in the risk prediction of complex human diseases. Many studies incorporated internal information, such as effect size distribution, or external information, such as linkage disequilibrium, functional annotation, and pleiotropy among multiple diseases, to optimize the performance of PRS. To leverage on multiomics datasets, we developed a novel flexible transcriptional risk score (TRS), in which messenger RNA expression levels were imputed and weighted for risk prediction. In simulation studies, we demonstrated that single-tissue TRS has greater prediction power than LDpred, especially when there is a large effect of gene expression on the phenotype. Multitissue TRS improves prediction accuracy when there are multiple tissues with independent contributions to disease risk. We applied our method to complex traits, including Crohn's disease, type 2 diabetes, and so on. The single-tissue TRS method outperformed LDpred and AnnoPred across the tested traits. The performance of multitissue TRS is trait-dependent. Moreover, our method can easily incorporate information from epigenomic and proteomic data upon the availability of reference datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.